Kimberly Blackwell

Kimberly Blackwell is currently the Chief Executive Officer at Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Previously, Kimberly was Chief Medical Officer at Tempus Labs and a scientific co-founder of Cereius Radiopharmaceuticals. Kimberly joined Tempus Labs from Eli Lilly where she served as Vice President of Early Phase Oncology and Immuno-oncology, driving clinical development of all pre-approval oncology agents. Before joining the biopharma sector, Kimberly was a Professor of Medicine and an Assistant Professor of Radiation of Oncology at Duke University Medical Center where she also led the Women’s Cancer Program, the Breast Cancer Program, and Strategic Relations initiatives. Kimberly holds a BA in Bioethics from Duke University and received her MD from the Mayo Clinic Medical School.